Efficacy and Safety of Atacicept in IgA Nephropathy

Stopped Study was terminated early as per sponsor decision due to unexpectedly slow enrollment.

Conditions

• IgA Nephropathy

Interventions

• DRUG: Placebo
• DRUG: Atacicept 25 mg
• DRUG: Atacicept 75 mg

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]